Gilmore O'Neill - Sep 4, 2024 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Signature
/s/ Gilmore O'Neill
Stock symbol
EDIT
Transactions as of
Sep 4, 2024
Transactions value $
-$5,325
Form type
4
Date filed
9/6/2024, 04:18 PM
Previous filing
Jun 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EDIT Common Stock Sale -$5.33K -1.56K -0.49% $3.42 314K Sep 4, 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2024. The sale does not represent a discretionary trade by the Reporting Person.
F2 This transaction was executed in multiple trades at prices ranging from $3.4246 to $3.4503. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.